|
News Image

Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.

By Mill Chart

Last update: Sep 22, 2023

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) was identified as an affordable growth stock by our stock screener. NYSE:NVO is showing great growth, but also scores well on profitability, solvency and liquidity. At the same time it seems to be priced reasonably. We'll explore this a bit deeper below.

Analyzing Growth Metrics

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NYSE:NVO scores a 8 out of 10:

  • NVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.64%, which is quite impressive.
  • NVO shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.69% yearly.
  • NVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.03%.
  • NVO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.64% yearly.
  • NVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.66% yearly.
  • The Revenue is expected to grow by 13.65% on average over the next years. This is quite good.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Analyzing Valuation Metrics

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NYSE:NVO has achieved a 8 out of 10:

  • Compared to the rest of the industry, the Price/Earnings ratio of NVO indicates a rather cheap valuation: NVO is cheaper than 83.09% of the companies listed in the same industry.
  • NVO's Price/Forward Earnings ratio is rather cheap when compared to the industry. NVO is cheaper than 81.64% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 19.01. NVO is valued slightly cheaper when compared to this.
  • Based on the Enterprise Value to EBITDA ratio, NVO is valued cheaper than 81.16% of the companies in the same industry.
  • 87.92% of the companies in the same industry are more expensive than NVO, based on the Price/Free Cash Flow ratio.
  • NVO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NVO has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as NVO's earnings are expected to grow with 27.32% in the coming years.

Evaluating Health: NYSE:NVO

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:NVO, the assigned 7 for health provides valuable insights:

  • An Altman-Z score of 6.61 indicates that NVO is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 6.61, NVO belongs to the best of the industry, outperforming 85.02% of the companies in the same industry.
  • NVO has a debt to FCF ratio of 0.38. This is a very positive value and a sign of high solvency as it would only need 0.38 years to pay back of all of its debts.
  • NVO's Debt to FCF ratio of 0.38 is amongst the best of the industry. NVO outperforms 95.65% of its industry peers.
  • NVO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
  • The current and quick ratio evaluation for NVO is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.

Evaluating Profitability: NYSE:NVO

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:NVO, the assigned 9 is noteworthy for profitability:

  • With an excellent Return On Assets value of 23.95%, NVO belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 74.32%, NVO belongs to the top of the industry, outperforming 97.10% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 55.96%, NVO belongs to the top of the industry, outperforming 99.03% of the companies in the same industry.
  • NVO had an Average Return On Invested Capital over the past 3 years of 49.65%. This is significantly above the industry average of 15.23%.
  • The 3 year average ROIC (49.65%) for NVO is below the current ROIC(55.96%), indicating increased profibility in the last year.
  • Looking at the Profit Margin, with a value of 33.40%, NVO belongs to the top of the industry, outperforming 96.62% of the companies in the same industry.
  • NVO has a better Operating Margin (42.80%) than 98.55% of its industry peers.
  • The Gross Margin of NVO (84.35%) is better than 87.44% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of NVO

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (12/8/2023, 7:07:33 PM)

Premarket: 96.5 -0.14 (-0.14%)

96.64

-0.17 (-0.18%)

NVO News

News Image2 hours ago - Yahoo FinanceOzempic, weight loss drugs fears settle into longer-term risks for food companies

Investors have fretted that weight loss drugs were going to overhaul the eating behaviors of consumers, health needs, and even wardrobes. So far, the fears have been overblown.

News Image2 hours ago - Yahoo FinanceNovo Nordisk's unique structure gives it an extra edge — and risk

Novo Nordisk's corporate structure has a few quirks that investors need to know about.

News Image2 hours ago - Yahoo FinanceNovo Nordisk is the 2023 Yahoo Finance Company of the Year

Novo Nordisk was the talk of the pharma and medical world this year — and also the world of People magazine and E! with stars from Amy Schumer to Elon Musk using the firm’s diabetes and weight-loss medicines, Ozempic and Wegovy. This is partly why Novo Nordisk is Yahoo Finance's 2023 Company of the Year.

News Image3 days ago - The Motley FoolWhy Viking Therapeutics Was Crushing It This Week

Nowadays, it's good to be a developer of next-generation weight loss drugs.

News Image3 days ago - The Motley FoolCould Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

These drugs address a rapidly growing market.

News Image4 days ago - Investor's Business DailyZoetis Stock A Good Companion For Your Portfolio? Shares Rising

Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.

News Image5 days ago - Seeking AlphaNovo Nordisk’s Wegovy beats older obesity drugs in adherence

A peer-reviewed study shows a higher patient adherence rate for Novo Nordisk's (NVO) new anti-obesity drug Wegovy compared to older weight loss drugs. Read more here.

News Image6 days ago - Seeking AlphaLawyers push to consolidate cases linked to weight loss drugs

Law firms are seeking to consolidate lawsuits related to side effects of GLP-1 class of drugs filed against Novo Nordisk (NVO) and Eli Lilly (LLY). Read more here.

News Image7 days ago - Investor's Business DailyRoche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker

Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.

News Image7 days ago - The Motley Fool1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could struggle to meet Wall Street's lofty expectations.

News Image11 days ago - ChartmillWill NOVO-NORDISK A/S-SPONS ADR breakout?

The technical analysis for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is highly positive, with a rating of 10 out of 10, suggesting a potential breakout.

News Image20 days ago - ChartmillDon't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.

While growth is established for NYSE:NVO, the stock's valuation remains reasonable.

NVO Links
Follow us for more